CCR5 and HIV infectious disease: We reported that sTLR2 directly interacted with the HIV PAMPs in vitro (e.g., p17, p24, and gp41), leading to significantly reduced NF-κB activation, IL-8 production, CCR5 expression, and HIV-infection in a dose-dependent manner (40, 43).